Clinical Research Directory
Browse clinical research sites, groups, and studies.
Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas
Sponsor: Blokhin's Russian Cancer Research Center
Summary
GLIOTARG trial is a large single-center observational cohort study designed to investigate chemotherapy and targeted therapy outcomes in recurrent malignant gliomas. The study includes patients with molecularly confirmed diagnoses according to the World Health Organization (WHO) 2021 classification of Central Nervous System (CNS) tumors: glioblastomas (IDH-wildtype, WHO grade 4), astrocytomas (IDH-mutant, WHO grade 3-4), and pleomorphic xanthoastrocytomas (WHO grade 2-3).
Official title: Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas: Large Single-Center Observational Cohort Study (GLIOTARG)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1000
Start Date
2026-02-01
Completion Date
2027-10-01
Last Updated
2026-03-04
Healthy Volunteers
No
Interventions
Bevacizumab-Containing Regimens
Patients receiving any line of therapy that includes bevacizumab (alone or in combination with other agents such as temozolomide, irinotecan, lomustine, carboplatin, etc.)
Non-Bevacizumab Regimens
Patients receiving conventional chemotherapy without bevacizumab (including temozolomide monotherapy, PCV regimen, nitrosoureas, platinum compounds, etc.)
BRAF ± MEK Targeted Therapy
Patients harboring BRAF mutations receiving targeted therapy with BRAF inhibitors (dabrafenib, vemurafenib) alone or in combination with MEK inhibitors (trametinib, cobimetinib), with or without concomitant chemotherapy
Locations (1)
Blokhin's Russian Cancer Research Center
Moscow, Russia